We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Targeted Chemo-elimination (TCE) of Malaria (TME)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01872702
First Posted: June 7, 2013
Last Update Posted: August 10, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Mahidol Oxford Tropical Medicine Research Unit
National Centre for Parasitology, Entomology and Malaria Control, Cambodia
Family Health International, Cambodia
Oxford University Clinical Research Unit, Vietnam
National Malaria Control Program, Vietnam
Myanmar Oxford Clinical Research Unit
National Malaria Control Program, Myanmar
Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU), Laos
Shoklo Malaria Research Unit
Information provided by (Responsible Party):
University of Oxford
  Purpose

The overall aim of this study is two fold:

  1. to pilot targeted chemo-elimination of plasmodium falciparum malaria in known areas of artemisinin resistance in South East Asia.
  2. to understand the micro-epidemiology of malaria in these areas; chiefly, the prevalence and importance to on-going transmission of sub-clinical p.f malaria infections.

Condition Intervention
Plasmodium Falciparum Malaria Drug: malaria elimination using DP and low-dose primaquine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Targeted Chemo-elimination (TCE) to Eradicate Malaria in Areas of Suspected or Proven Artemisinin Resistance in Southeast Asia and South Asia

Resource links provided by NLM:


Further study details as provided by University of Oxford:

Primary Outcome Measures:
  • prevalence of falciparum malaria measured by qPCR (quantitative real time polymerase chain reaction), 12 months after the first administration of treatment with dihydroartemisinin-piperaquine and primaquine. (1017-13 and 23-15) [ Time Frame: 12 months ]
    Percentage falls in asymptomatic malaria prevalence in the intervention villages vs control villages, as determined by highly sensitive qPCR, 12 months after the first administration of treatment with dihydroartemisinin-piperaquine and primaquine.

  • prevalence of falciparum malaria measured by qPCR (quantitative real time polymerase chain reaction), 12 months after the first administration of targeted malaria elimination (1015-13) [ Time Frame: 12 months ]
    Percentage falls in asymptomatic malaria prevalence in the intervention villages vs control villages, as determined by highly sensitive qPCR, 12 months after the first administration of treatment with dihydroartemisinin-piperaquine

  • prevalence of falciparum malaria measured by qPCR (quantitative real time polymerase chain reaction), 4 months after the first administration of target malaria-elimination (23-15) [ Time Frame: 4 months ]
    Percentage falls in asymptomatic malaria prevalence in the intervention villages vs control villages, as determined by highly sensitive qPCR, 4 months after the first administration of treatment with dihydroartemisinin-piperaquine and primaquine.


Secondary Outcome Measures:
  • Safety and acceptability of targeted malaria elimination (1017-13 and 1015-13) [ Time Frame: 12 months ]
    Safety and acceptability of targeted malaria elimination, evaluated by questionnaires filled out by participants or care givers.


Other Outcome Measures:
  • Effect on gametocyte carriage by targeted malaria elimination (1017-13 and 1015-13) [ Time Frame: 12 months ]
    Effect on gametocyte carriage by targeted malaria elimination, measured by the proportions of gametocyte carriers over the 12 month period

  • Characterize parasite carriage using highly sensitive techniques in four geographically separate sites where resistance to artemisinin has been documented (1017-13 and 1015-13) [ Time Frame: 12 months ]
    Characterize parasite carriage using by molecular analysis of parasite genotypes, markers of resistance and parasite population genetic structure

  • Acceptability of targeted Chemo-elimination of malaria measured by number of peaople participate (1017-13) [ Time Frame: 12 months ]
  • Cost estimates of targeted Chemo-elimination of malaria by sampling strategy (1017-13) [ Time Frame: 12 months ]
  • incidence of clinical malaria in the villages over the first 12 months (1015-13) [ Time Frame: 12 months ]
  • The proportion of Artemisinin resistance - P.falciparum infections (23-15) [ Time Frame: 12 months ]
  • Sensitivity of novel RDTs (HS RDT) [ Time Frame: 12 months ]
    (Laos site only)

  • Specificity of novel RDTs (HS RDT) [ Time Frame: 12 months ]
    (Laos site only)


Enrollment: 8000
Actual Study Start Date: April 2013
Study Completion Date: July 2017
Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: malaria elimination using DP and low-dose primaquine
Two villages randomly allocated to intervention (chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages the entire population will be invited to receive three, monthly rounds of treatment with dihydroartemisinin-piperaquine and primaqunine to kill malaria parasites. The micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.
Drug: malaria elimination using DP and low-dose primaquine
Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
Other Names:
  • Three monthly rounds of:
  • Dihydroartemisinin-piperaquine
  • Low-dose primaquine
No Intervention: Control villages

Two villages randomly allocated to control (no chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages only the micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.

From June 2013 to June 2014 Cambodia site conducted surveys with no medical intervention (treatment arm). In July 2015 Cambodia implemented the TCE protocol with two intervention and two control villages. Primaquine is not used in the TCE treatment regimen in Cambodia. Both studies were approved under OxTREC reference no. 1017-13 and 1015-13.


  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Months and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

OxTREC reference: 1017-13

Inclusion Criteria:

  • Age ≥6 months, male or female,
  • Written informed consent (by parent/guardian in case of children)

Exclusion Criteria:

  • Pregnant women will not receive primaquine (urine pregnancy tests will be performed on women of appropriate age groups before drug administration at each TCE round)
  • History of allergy or known contraindication to artemisinins, piperaquine or PQ
  • Those who are, in the opinion of the study clinician, ill at the time of drug administration

OxTREC reference: 1015-13

Inclusion Criteria

  • Age ≥6 months, male or female,
  • Written informed consent (by legally acceptable representative in case of children)
  • Healthy at the time of the survey or drug administration
  • Not pregnant

Exclusion Criteria

  • Significant non-compliance with study requirements
  • Loss to follow up
  • Suspected severe adverse events
  • Severe illness

OxTREC reference: 23-15

Part 1. qPCR survey for identification of potential TMT villages;

Inclusion criteria:

  • Males and females 18 and above
  • Written informed consent
  • Presence of any acute severe illness at the time of survey

Exclusion criteria:

• Pregnant women in their first trimester

Part 2. TMT villages will be given directly observed therapy (DOT) with DP for 3 days and PQ (0.25 mg/kg) will be given on day 1

Inclusion criteria for TMT

  • Age ≥one year, male and female,
  • Willing to provide consent for those 18 years and above. For children 10-18 years old, parents/guardians must provide consent, and the children must provide assent. For children below 10 years old, the parents/guardians must provide consent.

Exclusion criteria for TMT

  • History of allergy or known contraindication to artemisinins, piperaquine or PQ.
  • Refusal of treatment.
  • Pregnant women in their 1st trimester.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01872702


Locations
Cambodia
Pailin
Pailin, Cambodia, 372
Lao People's Democratic Republic
Savannakhet
Savannakhet, Lao People's Democratic Republic
Myanmar
Mahidol Oxford Clincal Research Unit, Myanmar
Rangoon, Myanmar
Thailand
Shoklo Malaria Research Unit
Mae Sot, Tak, Thailand
Vietnam
Oxford University Clinical Research Unit - Vietnam
Ho Chi Minh city, Vietnam, Ward 1, District 5
Sponsors and Collaborators
University of Oxford
Mahidol Oxford Tropical Medicine Research Unit
National Centre for Parasitology, Entomology and Malaria Control, Cambodia
Family Health International, Cambodia
Oxford University Clinical Research Unit, Vietnam
National Malaria Control Program, Vietnam
Myanmar Oxford Clinical Research Unit
National Malaria Control Program, Myanmar
Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU), Laos
Shoklo Malaria Research Unit
Investigators
Principal Investigator: Nicholas J White, PhD University of Oxford
  More Information

Additional Information:
Publications:
(2011) Global Plan for Artemisinin Resistance Containment. Geneva: World Health Organisation.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT01872702     History of Changes
Other Study ID Numbers: BAKMAL1305
First Submitted: June 4, 2013
First Posted: June 7, 2013
Last Update Posted: August 10, 2017
Last Verified: August 2017

Keywords provided by University of Oxford:
Malaria elimination
Chemotherapy
Epidemiology
South East Asia
Artemisinin resistance
Dihydroartemisinin piperaquine
Primaquine

Additional relevant MeSH terms:
Malaria
Malaria, Falciparum
Protozoan Infections
Parasitic Diseases
Primaquine
Piperaquine
Dihydroartemisinin
Artemisinins
Artemisinine
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents